home / stock / tsvt / tsvt news

TSVT News and Press, 2seventy bio Inc.

Stock Information
Company Name: 2seventy bio Inc.
Stock Symbol: TSVT
Market: NASDAQ
Website: 2seventybio.com
Menu
TSVT TSVT Quote TSVT Short TSVT News TSVT Articles TSVT Message Board
Get TSVT Alerts

News, Short Squeeze, Breakout and More Instantly...
TSVT - J&J says Carvykti beat standard drugs in late-stage blood cancer trial

2024-07-02 08:23:40 ET More on Johnson & Johnson Johnson & Johnson (JNJ) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Johnson & Johnson: Market Will Regret The Overreaction Johnson & Johnson (JNJ) Bernstein's 40th Annual Strateg...
TSVT - Novo Nordisk buys 2seventy bio's Hemophilia A program

2024-06-27 06:56:19 ET More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk hypertensio...

TSVT - 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million

- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...

TSVT - EU to require additional cancer risk labeling on CAR T therapies

2024-06-14 15:55:36 ET More on Bristol-Myers Squibb Company , Gilead Sciences, etc. Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Bristol-Myers...
TSVT - Goldman cuts 2seventy bio to neutral, cites competition concerns

2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

TSVT - Sell Recommendation Issued On TSVT By Goldman Sachs

2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...

TSVT - Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

2024-05-14 08:45:00 ET Summary Legend Biotech Corporation reported lower-than-expected Q1 earnings, reflecting struggles in Carvykti’s revenue generation despite strong market potential. Carvykti, despite superior indications compared to competitors, is hindered by high tox...
TSVT - 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript

2024-05-08 15:15:51 ET 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Conference Call May 8, 2024, 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer ...

TSVT - 2seventy bio GAAP EPS of -$1.01 misses by $0.20, revenue of $12.4M misses by $1.69M

2024-05-08 07:08:38 ET More on 2seventy bio 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround 2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

TSVT - 2seventy bio Q1 2024 Earnings Preview

2024-05-07 13:19:48 ET More on 2seventy bio 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround 2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...
Next 10